FDA Approves First Drug to Cross Blood-Brain Barrier

For kids with Hunter syndrome, existing treatments could help their bodies but left their brains behind. That changed this week when the FDA approved the first drug engineered to cross the blood-brain barrier and treat the cognitive symptoms of this rare genetic disorder.

The drug, Avlayah, represents a breakthrough for Hunter syndrome patients who previously had no way to address the neurological damage caused by their condition. Children with severe cases face organ dysfunction, joint problems, hearing loss, and impaired brain development that can become fatal in their teens.

San Francisco-based Denali Therapeutics designed the drug using a clever workaround. They attached their enzyme therapy to a molecule that binds to receptors on brain cells, essentially hitching a ride across the protective barrier that normally keeps drugs out of the brain.

The approach worked remarkably well in clinical trials. After 24 weeks of treatment, 93% of the 47 children in the study had sugar buildup levels in their spinal fluid return to normal ranges. These toxic sugars cause the progressive damage seen in Hunter syndrome.

The FDA approved Avlayah for children weighing at least 11 pounds who haven't yet developed severe neurological impairment. The weekly four-hour infusion will launch in two weeks, giving families access to treatment before irreversible brain damage occurs.

Hunter syndrome already appears on newborn screening tests, which means doctors can start treatment early. About 90% of Hunter syndrome patients develop neurological symptoms, so nearly all of the estimated 2,000 patients worldwide in commercial markets could benefit.

Why This Inspires

This approval matters far beyond Hunter syndrome. Denali CEO Ryan Watts calls Avlayah "the foundation" for an entire platform of brain-penetrating drugs. The company is already developing similar treatments for other genetic disorders like Sanfilippo syndrome, Pompe disease, and Gaucher disease.

Other companies are watching closely too. Several drug makers are testing this same transferrin receptor approach for Alzheimer's disease, which affects millions. The FDA's willingness to approve a brain-penetrating drug based on biological markers rather than years of clinical outcomes creates a faster regulatory pathway for future treatments.

The blood-brain barrier has blocked progress on neurological treatments for decades. Now there's a proven path forward, complete with FDA approval and real patients benefiting from therapy.

For families who've watched their children's minds slip away while body-focused treatments could only do so much, this approval brings something they haven't had before: hope that reaches the brain.